BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22640480)

  • 1. Modeling of Neuropeptide Receptors Y1, Y4, Y5, and Docking Studies with Neuropeptide Antagonist Analogues: Implications for Selectivity.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2004 Aug; 22(1):497-508. PubMed ID: 22640480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
    Cabrele C; Beck-Sickinger AG
    J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
    Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
    J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
    Gehlert DR; Shaw JL
    Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloning and characterization of rabbit neuropeptide Y receptor subtypes.
    Umeda T; Kanatani A; Iwaasa H
    Peptides; 2009 Aug; 30(8):1441-7. PubMed ID: 19481128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes.
    Fällmar H; Åkerberg H; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
    Neuropeptides; 2011 Aug; 45(4):293-300. PubMed ID: 21696823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
    Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
    Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
    J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
    Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
    Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A G protein-coupled receptor dimer imaging assay reveals selectively modified pharmacology of neuropeptide Y Y1/Y5 receptor heterodimers.
    Kilpatrick LE; Humphrys LJ; Holliday ND
    Mol Pharmacol; 2015 Apr; 87(4):718-32. PubMed ID: 25637604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
    Kask A; Rägo L; Harro J
    Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of the N-terminal domains from Y receptors probed by NMR spectroscopy.
    Zou C; Kumaran S; Walser R; Zerbe O
    J Pept Sci; 2009 Mar; 15(3):184-91. PubMed ID: 19125388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of G protein and phospholipase C-coupled agonist binding to the Y1 neuropeptide Y receptor in rat brain: sensitivity to G protein activators and inhibitors and to inhibitors of phospholipase C.
    Parker SL; Parker MS; Sweatman T; Crowley WR
    J Pharmacol Exp Ther; 1998 Jul; 286(1):382-91. PubMed ID: 9655883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture.
    Abounader R; Elhusseiny A; Cohen Z; Olivier A; Stanimirovic D; Quirion R; Hamel E
    J Cereb Blood Flow Metab; 1999 Feb; 19(2):155-63. PubMed ID: 10027771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
    Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
    Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains.
    Dumont Y; Jacques D; Bouchard P; Quirion R
    J Comp Neurol; 1998 Dec; 402(3):372-84. PubMed ID: 9853905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?
    Iyengar S; Li DL; Simmons RM
    J Pharmacol Exp Ther; 1999 May; 289(2):1031-40. PubMed ID: 10215684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hypothalamic neuropeptide Y in feeding and obesity.
    Gehlert DR
    Neuropeptides; 1999 Oct; 33(5):329-38. PubMed ID: 10657510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.